

Office of Vermont Health Access
January 10, 2006 DUR Board Approved PDL Changes
Effective February 1, 2006

Therapeutic Category	Preferred PDL status	Moved from PDL Preferred to Non-Preferred (PA required) Status	Comments
Alzheimer's Medications			
Cholinesterase/Glutamate Inhibitors	Namenda		
Analgesics			
Narcotics- Long Acting		Oramorph SR	No grandfathering for existing patients; Generic Morphine sulfate SR available on PDL
Anti-diabetics			
Thiazolidinediones	ActoPlus Met		Avandia and Avandamet also to be preferred when determined readily available in the market.
Anti-Emetics			
	Zofran	Kytril	Grandfathering: all patients with Kytril claims in their most recent <u>1-month</u> dispensing history. Managed via automated step-therapy protocol.
Anti-Hyperkinesia			
Long-Acting MPH Preps		Metadate CD; Ritalin LA; Focalin	Grandfathering: Currently-coded SPMI criteria will enable current users of these products to continue to receive them
Anti-Hypertensives			
ARBs	Teveten; Teveten HCT; Benicar; Benicar HCT		
Beta-Blockers			Coreg to be preferred when determined readily available in the market and upon preparation of clinical advisory.
CCB's		Dynacirc; Dynacirc CR	Grandfathering: all patients with Dynacirc/Dynacirc CR claims in their most recent <u>3-months</u> dispensing history. Managed via automated step-therapy protocol.
Anti-migraines			
Triptans	Imitrex	Zomig	Grandfathering: all patients with Zomig claims in their most recent <u>6-months</u> dispensing history. Managed via automated step-therapy protocol.
Anti-psychotics			
Atypicals & Combos	Geodon		
BPH			
Alpha Blockers		Uroxatral	Grandfathering: all patients with Uroxatral claims in their most recent <u>3-months</u> dispensing history. Managed via automated step-therapy protocol.
Androgen Hormone Inhibitors	Avodart		

Therapeutic Category	Preferred PDL status	Moved from PDL Preferred to Non-Preferred (PA required) Status	Comments
Glucocorticoids: Topical			
		Cloderm	No grandfathering.
Growth Hormone			
	Nutropin, Saizen, Tev-Topin, Norditropin <i>(Clinical PA still required for coverage)</i>		Promotion of preferred agents will impact new patient starts only through PA programming.
Fibric Acid Derivatives	Tricor, Triglide <i>(Still maintain required concomitant statin use)</i>		
Statins/Statin Combos		Altoprev	Grandfathering: all patients with Altoprev claims in their most recent <u>3-months</u> dispensing history. Managed via automated step-therapy protocol.
Multiple Sclerosis Injectables			
	Betaseron		
Ophthalmics			
Antihistamines	Patanol	Zaditor	No grandfathering.
Glaucoma Agents/Miotics		Azopt	Grandfathering: all patients with Azopt claims in their most recent <u>3-months</u> dispensing history. Managed via automated step-therapy protocol.
Mast Cell Stabilizers	Alamast		
Ossification Enhancers			
	Fosamax, Fosamax-D		
Parkinson's			
	Carbidopa/Levodopa (gen)	Sinemet- all forms (brand)	Grandfathering: all patients with brand Sinemet/Sinemet CR claims in their most recent <u>3-months</u> dispensing history. Managed via automated step-therapy protocol.
Platelet Inhibitors			
		Aggrenox	Grandfathering: all patients with Aggrenox claims in their most recent <u>3-months</u> dispensing history. Managed via automated step-therapy protocol.

Therapeutic Category	Preferred PDL status	Moved from PDL Preferred to Non-Preferred (PA required) Status	Comments
Psoriasis Injectibles			
	Enbrel, Raptiva <i>(Clinical PA still required for coverage)</i>		
Pulmonary			
Nasal Glucocorticoids	Flonase		
Urinary Antispasmodics			
	Ditropan XL, Vesicare <i>(pts < 65 yrs still require to step thru generic oxybutinin)</i>	Detrol LA	Grandfathering: all patients with Detrol-LA claims in their most recent <u>3</u> -months dispensing history. Grandfathering period will be limited to 3 months from the time of provider notification.